Teladoc Health (TDOC) earnings history
Most recent quarter
- Fiscal period
- Q2 2026
- Period end
- Jun 30, 2026
- EPS actual
- −$0.21
- EPS estimate
- −$0.25
- EPS surprise
- +15.90%
- Revenue surprise
- −1.38%
- Revenue
- $606.9M
- Revenue estimate
- $615.4M
- Reported
- Jul 29, 2026
Teladoc Health reported Q2 2026 results on July 29, 2026. The company posted a loss of $0.21 per share, narrower than the $0.25 loss expected, a 15.90% beat. Revenue was $606.9 million, about 1.4% below the $615.4 million consensus. Compared with Q2 2025, the loss widened slightly from $0.19 per share and revenue fell 4% from $631.9 million.
Every quarter in the table is a loss. Most were between $0.07 and $0.53 per share, but a few were far deeper: $41.58 in Q1 2022, $19.22 in Q2 2022, $23.49 in Q4 2022 and $4.92 in Q2 2024. Annual losses were $84.74 per share in 2022, $1.34 in 2023, $5.88 in 2024 and $1.14 in 2025. The first half of 2026 adds up to a loss of $0.57 per share, compared with $0.72 a year earlier. Revenue peaked at $660.5 million in Q4 2023 and has drifted lower since, with 2025 at $2.53 billion against $2.60 billion in 2023. Teladoc beat the EPS estimate in 11 of the last 20 quarters.
Teladoc reported Q3 between October 24 and October 30 in each of the past five years, which points to late October 2026 for the next report.
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Jul 29, 2026 | −$0.25 | −$0.21 | +15.90% | $606.9M | SEC |
| Q1 2026 | Apr 29, 2026 | −$0.34 | −$0.36 | −5.51% | $613.8M | SEC |
| Q4 2025 | Feb 25, 2026 | −$0.18 | −$0.14 | +21.92% | $642.3M | SEC |
| Q3 2025 | Oct 29, 2025 | −$0.26 | −$0.28 | −6.22% | $626.4M | SEC |
| Q2 2025 | Jul 29, 2025 | −$0.26 | −$0.19 | +26.33% | $631.9M | SEC |
| Q1 2025 | Apr 30, 2025 | −$0.34 | −$0.53 | −56.53% | $629.4M | SEC |
| Q4 2024 | Feb 26, 2025 | −$0.26 | −$0.28 | −7.03% | $640.5M | SEC |
| Q3 2024 | Oct 30, 2024 | −$0.28 | −$0.19 | +31.41% | $640.5M | SEC |
| Q2 2024 | Jul 31, 2024 | −$0.34 | −$4.92 | −1327.74% | $642.4M | SEC |
| Q1 2024 | Apr 25, 2024 | −$0.46 | −$0.49 | −6.85% | $646.1M | SEC |
| Q4 2023 | Feb 20, 2024 | −$0.22 | −$0.17 | +22.48% | $660.5M | SEC |
| Q3 2023 | Oct 24, 2023 | −$0.36 | −$0.35 | +3.98% | $660.2M | SEC |
| Q2 2023 | Jul 25, 2023 | −$0.41 | −$0.40 | +1.60% | $652.4M | SEC |
| Q1 2023 | Apr 26, 2023 | −$0.48 | −$0.42 | +13.24% | $629.2M | SEC |
| Q4 2022 | Feb 22, 2023 | −$0.25 | −$23.49 | −9452.66% | $637.7M | SEC |
| Q3 2022 | Oct 26, 2022 | −$0.57 | −$0.45 | +20.41% | $611.4M | SEC |
| Q2 2022 | Jul 27, 2022 | −$0.61 | −$19.22 | −3045.66% | $592.4M | SEC |
| Q1 2022 | Apr 27, 2022 | −$0.60 | −$41.58 | −6843.89% | $565.4M | SEC |
| Q4 2021 | Feb 22, 2022 | −$0.57 | −$0.07 | +87.68% | $554.2M | SEC |
| Q3 2021 | Oct 27, 2021 | −$0.67 | −$0.53 | +21.12% | $521.7M | SEC |
Quarterly revenue
Frequently asked questions
When did Teladoc Health (TDOC) last report earnings?
Teladoc Health last reported on Jul 29, 2026, covering fiscal Q2 2026.
Did TDOC beat earnings estimates?
Yes. Teladoc Health reported EPS of −$0.21 for Q2 2026 against a −$0.25 estimate — a 15.90% beat.
How much revenue did TDOC report last quarter?
Teladoc Health reported $606.9M in revenue for Q2 2026, against a consensus estimate of $615.4M.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.